The pharma roll-up has found great success buying businesses and slashing costs, but the size of its latest target raises concerns CEO MIchael Pearson may be biting off more than he can chew.
Can Valeant Work Its Magic On Allergan, Or Is Pearson Biting Off More Than He Can Chew?
Forbes - 22 Apr 2014 22:06
The pharma roll-up has found great success buying businesses and slashing costs, but the size of its latest target raises concerns CEO MIchael Pearson may be biting off more than he can chew.
Share this Article
Comment on this Article
Recommended
Please to comment